Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics Announces Cease Trade Order
TORONTO, ON / ACCESSWIRE / March 6, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r
Intellipharmaceutics International Inc. Announces Stock Option Grant
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International GAAP EPS of -$0.06
Intellipharmaceutics Announces Third Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re
Intellipharmaceutics International GAAP EPS of $0.00, Revenue of $480.21M
Intellipharmaceutics International Reports FY 2022 and Q1 2023 Results
Intellipharmaceutics International Inc. Brief: Recorded Net Loss for Q1 of US$355,738 or $0.01 per Common Shar
06:05 AM EDT, 06/06/2023 (MT Newswires) -- Intellipharmaceutics International Inc. Brief: Recorded net loss for Q1 of US$355,738 or $0.01 per common shar
Intellipharmaceutics International Inc. Brief: Announcing Cease Trade Order
05:14 PM EST, 03/07/2023 (MT Newswires) -- Intellipharmaceutics International Inc. Brief: Announcing Cease Trade Order
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Large Decline in Short Interest
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a significant drop in short interest in December. As of December 30th, there was short interest total
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Short Interest Update
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the target of a large increase in short interest in the month of November. As of November 15th, there was short intere
Intellipharmaceutics Inks License Deal With Taro for Depression Tablets Desvenlafaxine
Intellipharmaceutics International (OTC:IPCIF) on Tuesday said it had inked a Canadian license and supply agreement with Taro Pharmaceuticals (NYSE:TARO) for depression treatment desvenlafaxine. Share
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Drop in Short Interest
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest tot
Intellipharmaceutics International GAAP EPS of -$0.03
Intellipharmaceutics International press release (OTC:IPCIF): Q2 GAAP EPS of -$0.03. As of May 31, 2022, our cash balance was $372,795.
Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03
Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03
Intellipharmaceutics International reports Q3 results
Intellipharmaceutics International (OTC:IPCIF): Q3 GAAP EPS of -C$0.04.As of August 31, 2021, our cash balance was C$1.11MPress Release
The rise in residential prices in the US reached a new high in June, driven by low interest rates and tight housing
In a situation where housing supply is tight, low-interest loans spurred buyers to compete for prices, and US housing prices once again recorded the biggest increase in more than 30 years.
Apple Inc's new watch may be delayed due to production problems.
Apple Inc's upcoming smartwatch has encountered production problems because the manufacturer's adjustments to the new design may cause delays, according to a person familiar with the matter. It has been reported that the new watch is expected to have a larger screen and a faster processor. People familiar with the situation, who spoke on condition of anonymity, said the upgrade posed a challenge. According to earlier reports, the production of the new generation of Apple Inc watches has been delayed, mainly due to complex design. Apple Watch 7 manufacturers began small-scale production last week, but failed to meet satisfactory production targets, the report said. Apple Inc didn't immediately respond to a request for comment.
No Data